By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site.
Industry: Biotechnology
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
Institution %: 67.474
YTD Institution change: -13714
InsidersInsiders %: 1.376
Insiders Purchases YTD:
Insiders Sales YTD: 150000
Insiders Net YTD: -150000
Analyst RatingsTarget Price: 88.13
Overall Rating: 3.8214
Strong Buys (5): 11
Buys (4): 4
Holds (3): 11
Sells (2): 1
Strong Sells (1): 1
52 Week Hi: 76.19
52 Week Low: 37.55
Beta: 1.563
50 Day MA: 49.5206
200 Day MA: 52.1435
Earnings / Revenue TrendsQtr Earnings Growth YOY: 0
Qtr Revenue Growth YOY: 442.038
Forward PE:
Trailing PE: